Investment Rating - The report gives a "Recommended" rating for the company, indicating a potential upside of 5% to 20% relative to the benchmark index [18][22]. Core Insights - The company's main business, focusing on specialty APIs and intermediates, is expected to support stable profit growth. The company's technology and product layout in the small nucleic acid and peptide fields are anticipated to open up medium to long-term growth opportunities [22][44]. - The company achieved a revenue of 1.263 billion yuan in 2023, representing a year-on-year growth of 25.24%, with a net profit of 289.42 million yuan, up 37.19% year-on-year [19][20]. Summary by Sections Business Performance - The company's raw material and intermediate business generated sales revenue of 1.059 billion yuan in 2023, a year-on-year increase of 16.06%. The cardiovascular products revenue was 300 million yuan, up 26.94%, driven by strong sales of Eplerenone and Benazepril [3][31]. - The oncology products revenue reached 244 million yuan, a significant increase of 73.63%, mainly due to the growth in sales of Abiraterone [3][31]. - The women's health products, launched in 2021, achieved revenue of 189 million yuan in 2023, remaining stable year-on-year [3][31]. Financial Metrics - The overall gross margin for 2023 was 55.92%, an increase of 4.3 percentage points year-on-year, primarily due to the commencement of formulation sales, with the formulation segment's gross margin reaching 87.74% [8][20]. - The net profit margin was 22.90%, up 1.35 percentage points year-on-year, while the net profit margin after deducting non-recurring items was 20.71%, an increase of 0.2 percentage points [8][20]. Future Projections - Revenue projections for 2024-2026 are estimated at 1.624 billion, 2.020 billion, and 2.425 billion yuan, respectively, with year-on-year growth rates of 28.62%, 24.42%, and 20.01% [16][22]. - The expected net profit for the same period is projected to be 394.20 million, 515.00 million, and 658.77 million yuan, with growth rates of 36.20%, 30.65%, and 27.92% [16][22]. Product Development - The company has made significant progress in its integrated strategy of raw materials and formulations, with the Dydrogesterone tablet receiving approval as the first generic in China [19][40]. - The company has a rich reserve of APIs and is continuously advancing global registrations, with multiple products submitted for various international approvals [32][43].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 32.00, compared to the last closing price of 24.64 [1][4]. Core Views - The company's Q1 performance exceeded market expectations, driven by the accelerated growth in its formulation and peptide businesses [2][7]. - The company reported a revenue of 1.263 billion yuan for 2023, representing a year-over-year increase of 25.24%, and a net profit of 289 million yuan, up 37.19% year-over-year [2][5]. - In Q1 2024, the company achieved a revenue of 336 million yuan, reflecting an 11.08% year-over-year growth, and a net profit of 82 million yuan, which is a significant increase of 79.14% year-over-year [2][5]. Summary by Sections Financial Performance - For 2023, the company achieved a revenue of 1.263 billion yuan and a net profit of 289 million yuan, with a net profit margin of 24.49% [2][5]. - The Q1 2024 results showed a revenue of 336 million yuan and a net profit of 82 million yuan, both marking historical highs for the respective periods [2][5]. - The gross margin for Q1 2024 was reported at 53.68% [2]. Business Segments - The raw materials and intermediates segment generated sales of 1.059 billion yuan in 2023, accounting for 84.44% of total revenue, with a gross margin of 56.74% [2]. - The formulation business, which includes the newly approved Dydrogesterone tablets, is expected to accelerate growth, having already entered 1,058 hospitals by the end of 2023 [2][5]. Growth Prospects - The peptide drug market is projected to reach 96 billion USD by 2025, indicating significant growth potential for the company [2]. - The company plans to invest 279 million yuan to establish a production line for Semaglutide raw materials, expected to commence operations in mid-2024 [2]. - The company has established strategic partnerships in the peptide and oligonucleotide sectors, enhancing its growth prospects [2].

证券代码：605116 证券简称：奥锐特 公告编号：2024-023 重要内容提示： 投资者可于 2024 年 05 月 06 日(星期一)至 05 月 10 日(星期五)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aurisco.co m 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 奥锐特药业股份有限公司（以下简称"公司"）已于 2024 年 4 月 29 日发布 公司 2023 年年度报告和 2024 年第一季度报告，为便于广大投资者更全面深入地 了解公司 2023 年度和 2024 年第一季度的经营成果、财务状况，公司计划于 2024 年 05 月 13 日下午 15:00-16:30 举行 2023 年度暨 2024 年第一季度业绩说明会， 就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2023 年度和 2024 年第一季度的经营成果与投资者进行互动交流，在信息披露允许的范围内就投资 者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2024 年 05 月 13 日下午 ...

关于奥锐特药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 | | | 二、非经营性资金占用及其他关联资金往来情况汇总表 …………第 3一3 页 let 您可提用手机 "扫一扫" (规进入"注册在平台现在申请有载全讯网的会计网项方乐出页， 您可提用手机 "扫一扫" (规进人"注册会计算行业定一监管平台（http://www.m20864 非经营性资金占用及其他关联资金往来情况的 专项审计说明 委托单位：奥锐特药业股份有限公司 审计单位：天健会计师事务所（特殊普通合伙） 联系电话：0571-89722900 发 二、管理层的责任 奥锐特公司管理层的责任是提供真实、合法、完整的相关资料,按照《上市 公司监管指引第8号 -- 上市公司资金往来、对外担保的监管要求》(证监会公 告〔2022〕26 号)和《上海证券交易所上市公司自律监管指南第2 号 -- 业务 办理(2023年12月修订)》(上证函〔2023〕3870 号)的规定编制汇总表,并保 证其内容真实、准确、完整,不存在虚假记载、误导性陈述或重大遗漏。 诚信 公正 务实 专业 第 1 页 共 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-016 奥锐特药业股份有限公司 第三届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 奥锐特药业股份有限公司（以下简称"公司"）第三届董事会第六次会 议于 2024 年 4 月 25 日在公司会议室以现场结合通讯方式召开。本次会议的 通知于 2024 年 4 月 15 日以邮件方式送达全体董事、监事及高级管理人员， 会议由董事长彭志恩召集并主持，应到董事 9 人，实到董事 9 人。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》《奥 锐特药业股份有限公司章程》以及相关法律、法规的有关规定，会议形成的 决议合法有效。 二、董事会会议审议情况 （一）审议《关于公司<2023 年年度报告>及其摘要的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2023 年年度股东大会需听取独立董事述职报告。 （四）审议《关于公司董事会对独立董事独立性自查情况的专项报告》 表决结果：同意 9 票，反对 0 票，弃 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-022 奥锐特药业股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 召开的日期时间：2024 年 5 月 20 日 14 点 00 分 召开地点：浙江省台州市天台县八都工业园区隆兴路 1 号公司行政楼会议室 股东大会召开日期：2024年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 20 日 至 2024 年 5 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东 ...

奥锐特药业股份有限公司 2023 年度独立董事述职报告 （钟永成） 作为奥锐特药业股份有限公司(以下简称"公司")的独立董事,本人 严格按照《公司法》《证券法》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》《上市公司治理准则》等有关法律法规、规范性文 件及公司《章程》《独立董事工作细则》的规定和要求，报告期内（特指 2023年5月5日至2023年12月31日本人担任公司独立董事期间，下同）， 本人凭借丰富的会计专业知识和经验，积极参加公司董事会及各专门委员 会会议、股东大会，在董事会日常工作及决策中尽职尽责，对董事会审议 的重大事项发表了独立客观的意见，为董事会的科学决策提供支撑，促进 公司规范运作，有效保障全体股东权益不受损害。现将本人 2023 年度履 行独立董事职责情况汇报如下： 一、独立董事的基本情况及独立性说明 （一）本人工作履历、专业背景以及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域 积累了丰富的经验。本人个人工作履历、专业背景以及兼职情况如下： 本人钟永成,1964年出生,中共党员,本科学历, 2002年7月至今任浙 江中和联合会计师事务所（普通合伙） ...

目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 第 1 页 共 2 页 天健审〔2024〕3925 号 奥锐特药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了奥锐特药业股份有限公司（以下简称奥锐特公司）2023 年 12 月 31 日 的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是奥锐 特公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 我们认为，奥锐特公司于 2023 年 12 月 31 日按 ...

Financial Performance - The total revenue for the cardiovascular raw materials segment reached ¥300,413,911.15, representing a 26.94% increase compared to the previous year[21]. - The gross profit margin for the oncology raw materials segment was 43.33%, with a revenue increase of 73.63% year-over-year[21]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the last fiscal year, representing a growth of 20% year-over-year[133]. - The company reported a revenue of 1.5 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[136]. - The company has set a revenue guidance for the next fiscal year at 1.8 billion RMB, which reflects an expected growth of 20%[136]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming to reach 1.875 billion[133]. Research and Development - Research and development expenses decreased by 31.26% to ¥40,992,447.18 compared to the previous year[5]. - The company's R&D investment amounted to 6,707.27 million RMB, representing 8.77% of operating revenue and 4.59% of net assets[26]. - The average R&D investment in the same industry was 35,786.23 million RMB, with the company's R&D investment accounting for 10.84% of operating revenue and 6.96% of net assets during the reporting period[26]. - The company is focusing on technological innovation and cost reduction in existing products while seeking breakthroughs in new products[83]. - The company is focusing on developing new products in the raw material and formulation projects, with multiple new projects initiated in 2023[27]. - The company has 36 products currently under research, with multiple new products expected to enter the registration application stage in the next 3-5 years[83]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[136]. - The company has established six major engineering technology innovation platforms for the research and development of small molecule drugs, peptide drugs, and oligonucleotide drugs[56]. - The company has a professional research team composed of PhD, master's, and bachelor's degree holders, equipped with advanced R&D testing equipment including UPLC-MS and GC-MS[147]. Marketing and Sales - The company plans to expand its marketing network and strengthen customer relationships while penetrating markets in Europe, America, and Asia[38]. - Over 85% of the company's products were sold overseas during the reporting period, indicating a strong international market presence[64]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[133]. - A new strategic partnership was announced, expected to enhance distribution channels and increase sales by 15%[133]. - The company's marketing team utilizes various methods for market expansion, including global pharmaceutical exhibitions and customer visits[167]. Environmental and Safety Management - The company invested 2,874.48 million RMB in environmental protection in 2023, with plans to increase this investment in the future[41]. - The company is committed to improving its EHS management system to mitigate environmental and safety risks associated with its production processes[41]. - The company has established a standardized hazardous waste storage area with a total area of 380 m²[155]. - The company has implemented various wastewater and waste gas treatment processes, ensuring compliance with environmental standards[155][157]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[152]. - The company has undergone changes in its board of directors, with several independent directors being elected or replaced[160]. Governance and Compliance - The company emphasizes the importance of internal control and governance, ensuring compliance with relevant laws and regulations[65]. - The company has established a comprehensive and effective internal control system, ensuring all subsidiaries maintained effective internal controls without significant defects during the reporting period[127]. - The company received a standard unqualified opinion in its internal control audit report for 2023[151]. - The company has implemented corrective measures for identified management issues to continuously improve its internal control system[127]. - The company has a diverse board with members holding various positions in other companies, enhancing its strategic oversight capabilities[124]. Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.20 per 10 shares for the 2023 fiscal year, totaling RMB 89.3629 million, subject to shareholder approval[92]. - The company has approved a three-year shareholder return plan for 2023-2025 during the shareholder meeting[1]. - The company has a cash dividend policy that stipulates a minimum of 20% of the distributable profit should be distributed in cash if conditions allow[116]. - The company declared a cash dividend of 2.20 RMB per 10 shares, totaling 89,362,900 RMB, which represents 30.88% of the net profit attributable to ordinary shareholders in the consolidated financial statements[96]. Operational Efficiency - The company is focusing on enhancing production efficiency and product quality stability through continuous optimization of existing leading products[56]. - The company aims to improve operational efficiency by 15% through the implementation of advanced manufacturing technologies[136]. - The company has implemented upgrades to its waste gas treatment facilities, improving operational efficiency and treatment effectiveness[177]. Financial Management - The net cash flow from financing activities for 2023 was ¥49,019,558.18, compared to a negative ¥14,914,942.10 in the previous period[149]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to ¥17,156,238[159]. - The company plans to issue convertible bonds to raise funds for future projects, with a feasibility analysis report approved by the board[141].

一、独立董事的基本情况及独立性说明 （一）本人工作履历、专业背景以及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域 积累了丰富的经验。本人个人工作履历、专业背景以及兼职情况如下： 本人苏为科，1961年出生，民革党员，博士研究生学历，2001年7月 至今任浙江工业大学教授，曾主持或负责完成国家重点研发计划、"973" 前沿、"十一五"科技支撑计划、重大国际合作等国家级项目10余项、省 部级项目20余项，已有30余项重大科技成果实现产业化。取得3·1类原料 药批件1个和新药临床批件2个。主编《医药中间体制备方法》（2001化工 出版社）1部，参编《Ball Milling Towards Green Synthesis Applications, Projects, Challenges. 》（The Royal Society of Chemistry. UK, 2015） 1部，发表SCI收录论文200余篇，授权发明专利100余件。获国家科技发明 二等奖1项，省部级科技成果一等奖7项、中国专利优秀奖3项。荣获浙江 省特级专家，浙江省有突出贡献的专家称号，2014年获全国五一劳动奖状， ...